Gilead Sciences | Umsatzkosten



Cost Of Sales Veränderung Datum
AbbVie USD 4.35B 344M 2025-06
Agios Pharmaceuticals USD 1.7M 617K 2025-06
ALKERMES USD 49.46M 263K 2025-06
Alnylam Pharmaceuticals USD 142.95M 71.91M 2025-06
Amgen USD 3.01B 406M 2025-06
Biogen USD 605M 24.3M 2025-06
BioMarin Pharmaceutical USD 154.94M 3.38M 2025-06
Bristol-Myers Squibb USD 3.37B 339M 2025-06
Eli Lilly USD 2.45B 223.6M 2025-06
Gilead Sciences USD 1.5B 39M 2025-06
GlaxoSmithKline GBP 2.16B 241M 2025-06
Glaxosmithkline GBP 2.52B 199M 2024-12
Incyte USD 78.77M 10.96M 2025-06
J&J USD 7.6B 304M 2025-06
Merck USD 2.82B 53M 2025-06
Moderna USD 119M 29M 2025-06
Neurocrine Biosciences USD 11.3M 2.1M 2025-06
Novartis USD 3.32B 95M 2025-06
Pfizer USD 4.99B 2.4B 2025-06
PTC Therapeutics USD 15.48M 2.62M 2025-06
Regeneron Pharmaceuticals USD 530.2M 264.7M 2025-06
Sanofi EUR 2.99B 103M 2025-06
Sarepta Therapeutics USD 153.22M 15.66M 2025-06
United Therapeutics USD 175.2M 102.3M 2025-06
Vertex Pharmaceuticals USD 407.5M 44.5M 2025-06


Gilead Sciences Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Aug 2025.